Atherosclerosis vaccine - AFFiRiS

Drug Profile

Atherosclerosis vaccine - AFFiRiS

Alternative Names: ATH-03

Latest Information Update: 13 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFFiRiS
  • Class Antihyperlipidaemics; Vaccines
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 12 Jul 2012 Affiris completes a phase I trial in Healthy volunteers in Austria (NCT01284582)
  • 03 Nov 2011 Affiris completes enrolment in its phase I trial for Atherosclerosis in Austria (NCT01284582)
  • 19 May 2011 Phase-I clinical trials in Atherosclerosis in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top